One of the most notable studies in this field is a single-arm, Phase II clinical trial conducted by Brastianos et al. [64], which evaluated the efficacy of combined BRAF-MEK inhibition in patients with BRAF V600E-positive PCP. This evidence concerns the gene BRAF and pneumocystosis.